Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its technological innovations and diversification plans regarding its product portfolio.The optimism, led by a solid third ...

It has been about a month since the last earnings report for Nevro (NVRO). Shares have lost about 8.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

A month has gone by since the last earnings report for Nevro (NVRO). Shares have added about 15.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Thornal will join the orthopedics company as group president for global businesses and the Americas, a newly created position ...

Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts ...

Analysts' ratings for Nevro (NYSE:NVRO) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below offers a condensed view of their recent ratings, showcasing ...

After inking a deal worth up to $75 million to acquire joint pain devicemaker Vyrsa Technologies late last year, Nevro now appears to be trying to lessen the impact of those costs on its bottom line.

Nevro (NVRO) announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1 SI Joint Fusion System, a posterior integrated ...